Compare EVG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Current Price
| Metric | EVG | CDXS |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.9M | 154.4M |
| IPO Year | 2004 | 2008 |
| Metric | EVG | CDXS |
|---|---|---|
| Price | $9.96 | $1.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.14 |
| AVG Volume (30 Days) | 65.9K | ★ 845.5K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $5.02 |
| Revenue Next Year | N/A | $18.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $9.78 | $0.90 |
| 52 Week High | $11.25 | $2.98 |
| Indicator | EVG | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 47.51 |
| Support Level | $9.78 | $0.96 |
| Resistance Level | $10.95 | $1.29 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 8.28 | 55.81 |
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.